Health Professional Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Professional Times.

Press releases published on September 28, 2026

2 hours ago

NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes

Indeterminate GlobeNewswire

2 hours ago

ORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)

Indeterminate GlobeNewswire

2 hours ago

NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212

Indeterminate GlobeNewswire

2 hours ago

Callio Therapeutics Appoints Chris Hassig, PhD, as Chief Scientific Officer

Indeterminate GlobeNewswire

2 hours ago

Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer

Indeterminate GlobeNewswire

2 hours ago

Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer

Indeterminate GlobeNewswire

2 hours ago

CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit

Indeterminate GlobeNewswire

2 hours ago

U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Indeterminate GlobeNewswire

2 hours ago

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

Indeterminate GlobeNewswire

3 hours ago

4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company’s Phase I Cell Therapy Program

Indeterminate GlobeNewswire

3 hours ago

Pharmazz Completes Enrollment in 160-Patient Phase 4 Trial of Sovateltide in Acute Ischemic Stroke

Indeterminate GlobeNewswire

3 hours ago

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

Indeterminate GlobeNewswire

3 hours ago

Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine

Indeterminate GlobeNewswire

3 hours ago

BrewDog Builds Momentum for Next Growth Chapter with Expanded Senior Leadership Team

Indeterminate GlobeNewswire

3 hours ago

BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer

Indeterminate GlobeNewswire

3 hours ago

Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation

Indeterminate GlobeNewswire

3 hours ago

Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026

Indeterminate GlobeNewswire

3 hours ago

Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab

Indeterminate GlobeNewswire

3 hours ago

Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules

Indeterminate GlobeNewswire

3 hours ago

NOTICE TO DISREGARD -- Direct Meds

Indeterminate GlobeNewswire